Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Jamie Arnott, Jens C. Eickhoff, Michael A. Carducci, Anthony M. Treston, Justine Yang Bruce, George Wilding, Roberto Pili, Glenn Liu, Theodore F. Logan
Publikováno v:
Investigational New Drugs. 30:794-802
Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare. We conducted a multicenter phase I
Publikováno v:
Current Oncology Reports. 8:114-119
Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are s
Publikováno v:
Bone Marrow Transplantation. 30:805-812
Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be genera
Autor:
Kim Margolin, Theodore F. Logan, Janice P. Dutcher, Geoff Weiss, Michael B. Atkins, James W. Mier, Joseph I. Clark, Frederick R. Aronson, Jeffrey A. Sosman
Publikováno v:
Medical Oncology. 18:209-220
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regarding the efficacy of the high-dose interl
Autor:
Margaret A. Marshall, Amy P. Abernethy, Michael S. Gordon, John A. Glaspy, Bo Huang, Jesus Gomez-Navarro, Antoni Ribas, Theodore F. Logan, David H. Lawson, Bartosz Chmielowksi, Diana Gerhardt, Rene Gonzalez, Karl D. Lewis, Erjian Wang, Poe Hirr Hsyu, Jason Chesney
Publikováno v:
Journal of Translational Medicine, Vol 10, Iss 1, p 236 (2012)
Journal of Translational Medicine
Ribas, Antoni; Chesney, Jason A; Gordon, Michael S; Abernethy, Amy P; Logan, Theodore F; Lawson, David H; et al.(2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine, 10(1), 236. doi: http://dx.doi.org/10.1186/1479-5876-10-236. Retrieved from: http://www.escholarship.org/uc/item/08b3211x
Journal of Translational Medicine
Ribas, Antoni; Chesney, Jason A; Gordon, Michael S; Abernethy, Amy P; Logan, Theodore F; Lawson, David H; et al.(2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine, 10(1), 236. doi: http://dx.doi.org/10.1186/1479-5876-10-236. Retrieved from: http://www.escholarship.org/uc/item/08b3211x
Background CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall survival